Nathan J. Dowden Sells 1,018 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDAGet Rating) COO Nathan J. Dowden sold 1,018 shares of the stock in a transaction dated Friday, September 23rd. The shares were sold at an average price of $15.07, for a total transaction of $15,341.26. Following the completion of the sale, the chief operating officer now owns 64,355 shares of the company’s stock, valued at $969,829.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Entrada Therapeutics Trading Up 12.4 %

Entrada Therapeutics stock traded up $1.66 during midday trading on Friday, hitting $15.09. 38,563 shares of the stock were exchanged, compared to its average volume of 91,097. Entrada Therapeutics, Inc. has a fifty-two week low of $5.12 and a fifty-two week high of $36.85. The stock has a market capitalization of $473.34 million and a price-to-earnings ratio of -1.25. The stock’s 50-day simple moving average is $12.63 and its 200 day simple moving average is $9.90.

Entrada Therapeutics (NASDAQ:TRDAGet Rating) last released its quarterly earnings data on Thursday, August 11th. The company reported ($0.74) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Entrada Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. New York State Common Retirement Fund acquired a new stake in Entrada Therapeutics during the first quarter worth about $46,000. Bank of New York Mellon Corp increased its position in shares of Entrada Therapeutics by 60.6% during the first quarter. Bank of New York Mellon Corp now owns 21,933 shares of the company’s stock valued at $206,000 after acquiring an additional 8,276 shares during the last quarter. Ghisallo Capital Management LLC acquired a new stake in shares of Entrada Therapeutics during the fourth quarter valued at about $257,000. Walleye Capital LLC acquired a new stake in shares of Entrada Therapeutics during the first quarter valued at about $419,000. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Entrada Therapeutics by 7.3% during the first quarter. Charles Schwab Investment Management Inc. now owns 68,704 shares of the company’s stock valued at $646,000 after acquiring an additional 4,685 shares during the last quarter. 79.02% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group increased their target price on shares of Entrada Therapeutics from $10.00 to $13.00 and gave the company a “neutral” rating in a research report on Tuesday, August 16th.

About Entrada Therapeutics

(Get Rating)

Entrada Therapeutics, Inc, a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1.

Featured Stories

Insider Buying and Selling by Quarter for Entrada Therapeutics (NASDAQ:TRDA)

Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.